| Literature DB >> 30464181 |
Anna Fečíková1, Robert Jech2, Václav Čejka1,3, Václav Čapek1, Daniela Šťastná4, Ivana Štětkářová5, Karsten Mueller6, Matthias L Schroeter6,7, Filip Růžička1, Dušan Urgošík8.
Abstract
Clinical benefits of pallidal deep brain stimulation (GPi DBS) in dystonia increase relatively slowly suggesting slow plastic processes in the motor network. Twenty-two patients with dystonia of various distribution and etiology treated by chronic GPi DBS and 22 healthy subjects were examined for short-latency intracortical inhibition of the motor cortex elicited by paired transcranial magnetic stimulation. The relationships between grey matter volume and intracortical inhibition considering the long-term clinical outcome and states of the GPi DBS were analysed. The acute effects of GPi DBS were associated with a shortening of the motor response whereas the grey matter of chronically treated patients with a better clinical outcome showed hypertrophy of the supplementary motor area and cerebellar vermis. In addition, the volume of the cerebellar hemispheres of patients correlated with the improvement of intracortical inhibition which was generally less effective in patients than in controls regardless of the DBS states. Importantly, good responders to GPi DBS showed a similar level of short-latency intracortical inhibition in the motor cortex as healthy controls whereas non-responders were unable to increase it. All these results support the multilevel impact of effective DBS on the motor networks in dystonia and suggest potential biomarkers of responsiveness to this treatment.Entities:
Mesh:
Year: 2018 PMID: 30464181 PMCID: PMC6249276 DOI: 10.1038/s41598-018-34880-z
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Short-latency intracortical inhibition (SICI) in dystonic patients in both states (GPi DBS ON and OFF) and in control subjects. The SICI was expressed as % amplitude of MEP (±SEM) elicited by a single unconditioned TMS pulse. (A) Dystonic patients in both states (GPi DBS OFF and ON) have less effective SICI (=higher % of unconditioned MEP) than controls with no difference between DBS ON and OFF states. The SICI was averaged from both the APB and ADM muscles and from all three AMT intensities (70%, 80%, 90%) of the conditioning stimulus in the paired TMS paradigm. (B) The SICI was more effective with an increasing AMT intensity of the conditioning TMS stimulus in control subjects. Dystonic patients have less effective SICI (=higher % of unconditioned MEP) with 80% and 90% of the AMT intensity of the conditioning stimulus in both GPi DBS states. The SICI was averaged from both the APB and ADM muscles. (C) Non-responders and partial responders had less effective SICI (=higher % of unconditioned MEP) with 90% AMT intensity of the conditioning stimulus in comparison with control subjects. Good responders had more effective SICI (=lower % of unconditioned MEP) with 70% AMT intensity of the conditioning stimulus. The SICI was averaged from both the APB and ADM muscles and from both the GPi DBS OFF and ON states. APB = Abductor Pollicis Brevis muscle, ADM = Abductor Digiti Minimi muscle, AMT = Active Motor Threshold, GR = good responders (>50% benefit), PR = partial responders (25–50% benefit), NR = non-responders (<25% benefit), CS = control subjects, *p < 0.05, **p < 0.01, ***p < 0.001.
Figure 2MEP onset latency in dystonic patients during both states (GPi DBS ON and OFF) in comparison with control subjects. The MEP onset latency was expressed as an average (±SEM) from both the single and paired pulse TMS paradigms and from both the APB and ADM muscles. (A) Control subjects had shorter MEP onset latency than dystonic patients in both GPi DBS states. Switching the GPi DBS to ON caused a shortening of the MEP onset latency in comparison with the OFF state. (B) The MEP onset latency differed according to the clinical benefit of the GPi DBS treatment in comparison with the preoperative state. While good responders had the MEP onset latency longer than control subjects, partial responders and non-responders had the MEP onset latency shorter than control subjects. APB = Abductor Pollicis Brevis muscle, ADM = Abductor Digiti Minimi muscle, GR = good responders (>50% benefit), PR = partial responders (25–50% benefit), NR = non-responders (<25% benefit), CS = control subjects, **p < 0.01, ***p < 0.001.
Figure 3Comparison of GM density between GPi DBS treated dystonia patients and control subjects. Age and total intracranial volume were used as nuisance vectors. Glass brain (A) and perpendicular projections (B) on an average T1-weighted brain MRI showing higher GM density in the cluster involving the SMA and anterior/middle cingulate and in the vermis of the cerebellum in all patients (PGR+PR+NR) compared to CS (p < 0.05 FWE corrected at peak level). (C) Clusters similar to the PGR+PR+NR > CS contrast were also obtained in contrasts PGR+PR > CS and PGR+PR > PN suggesting that the GM was selectively increased in good responders (GR) and partial responders (PR) compared to non-responders (NR) or control subjects (CS)(p < 0.05 FWE corrected at peak level). (D) – Correlation of the GM with % change in the adjusted dystonic score at the voxel x = -9, y = 10, z = 46 (red star) was significant (r = 0.87, p < 0.000001) in the middle cingulate cortex and ventral SMA where the increase of GM density with an increasing change of the adjusted dystonic score was found (image p < 0.05 FWE corrected at cluster level).
Figure 4Inverse correlation of the SICI with GM density in GPi DBS treated dystonia patients. Age and total intracranial volume were used as nuisance vectors. The average SICI (elicited with 70%, 80%, 90% AMT intensity of the conditioning stimulus in the paired TMS paradigm in both the APB and ADM muscles and in both the GPi DBS OFF and ON states) was used in the model. (A) Glass brain and two projections (B) on an average T1-weighted brain MRI show the clusters in the cerebellar hemispheres (p < 0.05 FWE corrected at cluster level) whose GM density inversely correlated with the SICI. The linear regression at the voxel of maximum correlation x = 34, y = −48, z = −52 is shown (r = −0.77, p < 0001). (C) Three separate results of post hoc analyses showing the contrast between GM in good responders (GR) and control subjects (CS) according to various AMT intensity (70%, 80% and 90%) of the conditioning stimulus (p < 0.001). The GM contrast was maximally pronounced with 70% intensity, less with 80% intensity and no difference was detected with 90% intensity. These gradual differences in GM density are similar to contrasts of SICI between good responders (GR) and control subjects (CS).
Figure 5Correlation of the MEP onset latency with the GM density in both groups of subjects. The MEP was elicited by the single TMS pulse in the APB muscle in control subjects and in GPi DBS treated patients during OFF state. (A) Glass brain and three projections on average T1-weighted brain MRI show the cluster of positive correlation in the left cerebellum (9, crus 1) (p < 0.05 FWE corrected for volume of cerebellum). (B) Regression line between the MEP onset latency and the GM density at voxel with maximum correlation [−14, −50, −44](r = 0.58, p < 0.001).
Descriptive data of the dystonia patients.
| Age at Onset (years) | Age at Surgery (years) | Etiology | Body Distribution | Dystonia Duration (years) | GPi DBS Duration (years) | BFMDS preop | BFMDS GPi DBS ON | BFMDS GPi DBS OFF | Medication (daily dose) |
|---|---|---|---|---|---|---|---|---|---|
| adulthood | 56 | idiopathic | generalized | 12 | 4 | 39 | 28.5 | 28.5 | biperiden 16 mg, |
| childhood | 20 | DYT 1 | generalized | 25 | 6 | 27 | 2.5 | 4.5 | 0 |
| adulthood | 51 | PINK 1 | generalized | 28 | 3 | 50 | 22.5 | 32 | escitalopram 10 mg, Botulinum toxin A |
| childhood | 26 | post-anoxic | generalized | 16 | 1 | 47.5 | 46 | 51 | clonazepam 2.5 mg, baclofen 20 mg, biperiden 3 mg, valproate 600 mg, venlafaxine 150 mg, Botulinum toxin A |
| childhood | 13 | DYT 1 | generalized | 11 | 5 | 28.5 | 14 | 21 | 0 |
| childhood | 18 | PKAN | generalized | 18 | 9 | 77.5 | 55 | 61 | clonazepam 1.5 mg, biperiden 3 mg, pantothenate 500 mg, Botulinum toxin A |
| childhood | 16 | PKAN | generalized | 16 | 8 | 70.5 | 80 | 82 | biperiden 18 mg, clonazepam 3.75 mg, baclofen 30 mg, panthotenate 500 mg, citalopram 40 mg, Botulinum toxin A |
| infancy | 30 | post-anoxic | generalized | 32 | 3 | 50.5 | 47.5 | 47.5 | 0 |
| adulthood | 65 | idiopathic | generalized | 11 | 4 | 15 | x | 12 | mirtazapine 30 mg |
| adulthood | 69 | idiopathic | generalized | 13 | 3 | 8 | 0 | 0 | 0 |
| adulthood | 53 | KMT2B | generalized | 15 | 5 | 20.5 | 7 | x | 0 |
| adulthood | 36 | idiopathic | generalized | 18 | 6 | 29 | 24.5 | 24.5 | clonazepam 1 mg, amitriptyline 50 mg, citalopram 40 mg, gabapentin 1800 mg |
| adulthood | 52 | idiopathic | generalized | 11 | 2 | 33 | 13.5 | 15.5 | trazodone 150 mg, venlafaxine 150 mg, |
| adulthood | 61 | idiopathic | generalized | 11 | 3 | 21 | 12.5 | 15.5 | bromazepam 2.25 mg, venlafaxine 150 mg, |
| adulthood | 73 | idiopathic | generalized | 8 | 1 | 16 | 15.5 | 18.5 | levodopa 1250 mg, carbidopa 125 mg, clonazepam 0.75 mg, sertraline 100 mg |
|
|
|
| |||||||
| adulthood | 41 | idiopathic | cervical | 23 | 4 | 24 | 17 | 19 | alprazolam 0.5 mg, citalopram 60 mg, Botulinum toxin A |
| adulthood | 48 | idiopathic | cervical | 18 | 4 | 20 | 16 | 19 | baclofen 30 mg, venlafaxine 150 mg, promethazin 25 mg, |
| adulthood | 47 | idiopathic | cervical | 10 | 1 | 26 | 22 | 22 | clonazepam 1 mg, primidone 500 mg, citalopram 20 mg, Botulinum toxin A |
| adulthood | 38 | idiopathic | cervical | 12 | 5 | 24 | 5 | 19 | 0 |
| adulthood | 74 | idiopathic | cervical | 13 | 3 | 25 | 22 | 22 | clonazepam 0.25 mg, citalopram 10 mg, Botulinum toxin A |
| childhood | 52 | idiopathic | cervical | 11 | 4 | 29 | 6 | 13 | 0 |
| adulthood | 51 | idiopathic | cervical | 16 | 7 | 24 | 14 | 22 | biperiden 2 mg, clonazepam 0.5 mg, sertraline 100 mg, |
The GPi DBS parameters.
| Patient | Right GPi DBS | Left GPi DBS | Implantable Generator | Electrodes | ||||
|---|---|---|---|---|---|---|---|---|
| Amplitude | Pulse Width [µs] | Frequency [Hz] | Amplitude | Pulse Width [µs] | Frequency [Hz] | |||
| 1 | 2.6 mA | 400 | 70 | 1.9 mA | 400 | 70 | Brio, St.Jude | 6148 |
| 2 | 1.5 V | 450 | 100 | 1.5 V | 450 | 100 | RC Activa, Medtronic | 3389 |
| 3 | 1.65 mA | 212 | 130 | 1.35 mA | 212 | 130 | Brio, St.Jude | 6148 |
| 4 | 0.9 mA | 162 | 50 | 1.2 mA | 162 | 50 | Brio, St.Jude | 6148 |
| 5 | 2.0 V | 240 | 130 | 2.6 V | 240 | 130 | RC Activa, Medtronic | 3389 |
| 6 | 1.8 V | 450 | 130 | 1.8 V | 450 | 130 | RC Activa, Medtronic | 3389 |
| 7 | 1.4 V | 450 | 130 | 1.3 V | 450 | 130 | RC Activa, Medtronic | 3389 |
| 8 | 1.6 mA | 170 | 90 | 1.9 mA | 180 | 90 | RC Activa, Medtronic | 3389 |
| 9 | 1.0 V | 450 | 200 | 1.0 V | 450 | 200 | RC Activa, Medtronic | 3389 |
| 10 | 2.5 V | 180 | 130 | 2.5 V | 180 | 130 | Kinetra, Medtronic | 3389 |
| 11 | 1.8 V | 210 | 130 | 1.8 V | 210 | 130 | RC Activa, Medtronic | 3389 |
| 12 | 2.4 V | 450 | 130 | 2.4 V | 450 | 130 | RC Activa, Medtronic | 3389 |
| 13 | 3.0 mA | 300 | 130 | 3.0 mA | 300 | 130 | Brio, St.Jude | 6148 |
| 14 | 1.9 mA | 360 | 50 | 1.9 mA | 360 | 50 | RC Activa, Medtronic | 3389 |
| 15 | 1.5 mA | 208 | 190 | 1.5 mA | 208 | 190 | Libra, St.Jude | 6148 |
| 16 | 1.5 mA | 180 | 100 | 1.6 mA | 180 | 100 | RC Activa, Medtronic | 3389 |
| 17 | 1.8 V | 360 | 60 | 1.8 V | 360 | 60 | RC Activa, Medtronic | 3389 |
| 18 | 1.4 mA | 212 | 130 | 1.5 mA | 212 | 130 | Brio, St.Jude | 6148 |
| 19 | 1.8 V | 180 | 130 | 1.6 V | 180 | 130 | RC Activa, Medtronic | 3389 |
| 20 | 2.2 V | 240 | 60 | 2.2 V | 240 | 60 | Kinetra, Medtronic | 3389 |
| 21 | 1.8 V | 180 | 130 | 1.8 V | 180 | 130 | RC Activa, Medtronic | 3389 |
| 22 | 1.4 V | 300 | 130 | 1.4 V | 300 | 130 | Kinetra, Medtronic | 3389 |
Amplitude is in [V], if voltage mode of DBS was used; amplitude is in [mA], if current mode of DBS was used.